ID: ALA5278854

Max Phase: Preclinical

Molecular Formula: C55H86N16O17

Molecular Weight: 1243.39

Associated Items:

Representations

Canonical SMILES:  CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O

Standard InChI:  InChI=1S/C55H86N16O17/c1-28(2)19-33(57)45(78)65-36(21-30-12-14-32(73)15-13-30)48(81)68-39(20-29(3)4)53(86)71-18-8-11-42(71)52(85)64-34(9-5-6-16-56)46(79)66-37(22-31-25-60-27-62-31)49(82)70-41(26-72)51(84)67-38(23-43(74)75)50(83)63-35(10-7-17-61-55(58)59)47(80)69-40(54(87)88)24-44(76)77/h12-15,25,27-29,33-42,72-73H,5-11,16-24,26,56-57H2,1-4H3,(H,60,62)(H,63,83)(H,64,85)(H,65,78)(H,66,79)(H,67,84)(H,68,81)(H,69,80)(H,70,82)(H,74,75)(H,76,77)(H,87,88)(H4,58,59,61)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m0/s1

Standard InChI Key:  NHJUFNWIIVOTIH-NUDUWCFGSA-N

Associated Targets(Human)

PCSK9/LDLR 155 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HMG-CoA reductase 2475 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 1243.39Molecular Weight (Monoisotopic): 1242.6357AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Ahamad S, Bhat SA..  (2022)  Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.,  65  (23.0): [PMID:36446632] [10.1021/acs.jmedchem.2c01290]

Source